[Personal characteristics of patients with cerebral microangiopathy].

Q3 Medicine

Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova Pub Date : 2025-01-01 DOI:10.17116/jnevro202512503151

T A Slyusar, Yu V Abramenko, I N Slyusar, V N Abramova, A B Antoshina

{"title":"[Personal characteristics of patients with cerebral microangiopathy].","authors":"T A Slyusar, Yu V Abramenko, I N Slyusar, V N Abramova, A B Antoshina","doi":"10.17116/jnevro202512503151","DOIUrl":null,"url":null,"abstract":"Objective: To study the personality characteristics of patients with cerebral microangiopathy (CMA) and evaluate the effect of sequential therapy with Mexidol (500 mg injections intravenously for 14 days) and Mexidol FORTE 250 (250 mg tablets 3 times a day for 60 days) on the personal characteristics of patients with CMA.Material and methods: 130 patients aged 55-70 years (72 women and 58 men) with CMA, who received Mexidol as part of the complex treatment according to the specified scheme. The neuropsychological study included the study of personality traits using the multifactorial personality questionnaire of R. Cattell and the Freiburg personality questionnaire, MRI. The neuropsychological examination included the study of personality characteristics using the R. Cattell multifactorial personality research questionnaire (form C) and the Freiburg Personality Questionnaire (variant B).Results: Patients with CMA were characterized by heterogeneity of personality characteristics, the severity and diversity of which changed as the disease progressed. The course of treatment with Mexidol led to a decrease in the representation and severity of personality changes.Conclusion: The high efficacy and safety of long-term sequential therapy with Mexidol and Mexidol FORTE 250 has been demonstrated.","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 3","pages":"51-56"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17116/jnevro202512503151","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To study the personality characteristics of patients with cerebral microangiopathy (CMA) and evaluate the effect of sequential therapy with Mexidol (500 mg injections intravenously for 14 days) and Mexidol FORTE 250 (250 mg tablets 3 times a day for 60 days) on the personal characteristics of patients with CMA.

Material and methods: 130 patients aged 55-70 years (72 women and 58 men) with CMA, who received Mexidol as part of the complex treatment according to the specified scheme. The neuropsychological study included the study of personality traits using the multifactorial personality questionnaire of R. Cattell and the Freiburg personality questionnaire, MRI. The neuropsychological examination included the study of personality characteristics using the R. Cattell multifactorial personality research questionnaire (form C) and the Freiburg Personality Questionnaire (variant B).

Results: Patients with CMA were characterized by heterogeneity of personality characteristics, the severity and diversity of which changed as the disease progressed. The course of treatment with Mexidol led to a decrease in the representation and severity of personality changes.

Conclusion: The high efficacy and safety of long-term sequential therapy with Mexidol and Mexidol FORTE 250 has been demonstrated.

查看原文本刊更多论文

【脑微血管病患者的个人特征】。

目的：研究脑微血管病（CMA）患者的人格特征，评价顺序治疗美西多（500 mg静脉注射，连续14天）和美西多FORTE 250 （250 mg片，每日3次，连续60天）对CMA患者人格特征的影响。材料和方法：130例55-70岁CMA患者（女性72例，男性58例），按照规定方案接受Mexidol作为综合治疗的一部分。神经心理学研究采用R. Cattell多因素人格问卷和Freiburg人格问卷进行人格特征研究。神经心理检查采用R. Cattell多因素人格调查问卷(C)和Freiburg人格调查问卷(B)进行人格特征研究。结果：CMA患者人格特征具有异质性，其严重程度和多样性随疾病进展而改变。用墨西多治疗的过程减少了人格改变的表现和严重程度。结论：长期序贯治疗美西多和美西多FORTE 250的有效性和安全性已得到证实。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova 医学-精神病学

CiteScore

1.10

自引率

0.00%

发文量

287

审稿时长

3-6 weeks

期刊介绍： Одно из старейших медицинских изданий России, основанное в 1901 году. Создание журнала связано с именами выдающихся деятелей отечественной медицины, вошедших в историю мировой психиатрии и неврологии, – С.С. Корсакова и А.Я. Кожевникова. Широкий диапазон предлагаемых журналом материалов и разнообразие форм их представления привлекают внимание научных работников и врачей, опытных и начинающих медиков, причем не только неврологов и психиатров, но и специалистов смежных областей медицины.